At Pfizer, A Split A Decade In The Making
Executive Summary
Pfizer's ambitious plans to spin out its Upjohn branded and generics business will result in a smaller, innovation-focused pharma. The decision comes after nine years of back-and-forth about whether the move would unlock value.
You may also be interested in...
A Slimmed-Down Pfizer Sets A New R&D Goal: 25 Launches By 2025
The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.
Merck To Spin Out A New Company, Following Industry's Downsizing Trend
Merck will spinout its mature franchises, including women's health products, into a new company that will have about $6bn-$6.5bn in 2021 revenues and be poised for modest growth.
Pfizer Delivers On Biosimilars Strategy
Pfizer's biosimilars franchise is well on its way to becoming a blockbuster business, three years after the company launched its first US biosimilar.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports